Novartis Foundation Symposium 243 – Mechanisms of Drug Resistance in Epilepsy – Lessons from Oncology

Chair′s Introduction (V. Ling).
<br />
<br /> The problem of the drug–resistant epilepsies (J. W. Sander).
<br />
<br /> Drug resistance molecules: lessons from oncology (George L. Scheffer and Rik J. Scheper).
<br />
<br /> Drug resistance in epilepsy: the role of the blood–brain barrier (N. Joan Abbott, et al.).
<br />
<br /> P glycoprotein and the mechanism of multidrug resistance (A. Varadi, et al).
<br />
<br /> Drug resistance caused by multidrug resistance–associated proteins (J. Wijnholds).
<br />
<br /> Reversal of multidrug resistance: lessons from clinical oncology (S. E. Bates, et al.).
<br />
<br /> Clinical development of P glycoprotein modulators in oncology (A. Oza).
<br />
<br /> Gene expression profiling of epothilone A–resistant cells (P. Atadja, et al.).
<br />
<br /> Imaging of P glycoprotein function in vivo with PET (N. H. Hendrikse and W. Vaalburg).
<br />
<br /> Animal models of drug–resistant epilepsy (W. Loscher).
<br />
<br /> Drug resistance in epilepsy: human epilepsy (S. M. Sisodiya, et al).
<br />
<br /> Cellular mechanisms of pharmacoresistance in slices from epilepsy surgery (R. A. Deisz).
<br />
<br /> Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo (U. Brinkmann).
<br />
<br /> OC144–093, a novel P glycoprotein inhibitor for the enhancement of anti–epileptic therapy (M. J. Newman, et al.).
<br />
<br /> Closing remarks (V. Ling).
<br />
<br /> Index of contributors.
<br />
<br /> Subject Index.